Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. Patil ST, et al. Among authors: johnson bg. Nat Med. 2007 Sep;13(9):1102-7. doi: 10.1038/nm1632. Epub 2007 Sep 2. Nat Med. 2007. PMID: 17767166 Clinical Trial.
Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.
Monn JA, Massey SM, Valli MJ, Henry SS, Stephenson GA, Bures M, Hérin M, Catlow J, Giera D, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD. Monn JA, et al. Among authors: johnson bg. J Med Chem. 2007 Jan 25;50(2):233-40. doi: 10.1021/jm060917u. J Med Chem. 2007. PMID: 17228865
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD. Rorick-Kehn LM, et al. Among authors: johnson bg. Psychopharmacology (Berl). 2007 Jul;193(1):121-36. doi: 10.1007/s00213-007-0758-3. Epub 2007 Mar 24. Psychopharmacology (Berl). 2007. PMID: 17384937
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Fell MJ, et al. Among authors: johnson bg. J Pharmacol Exp Ther. 2008 Jul;326(1):209-17. doi: 10.1124/jpet.108.136861. Epub 2008 Apr 18. J Pharmacol Exp Ther. 2008. PMID: 18424625 Free article.
Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.
Dominguez C, Prieto L, Valli MJ, Massey SM, Bures M, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD, Monn JA. Dominguez C, et al. Among authors: johnson bg. J Med Chem. 2005 May 19;48(10):3605-12. doi: 10.1021/jm040222y. J Med Chem. 2005. PMID: 15887967
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD. Rorick-Kehn LM, et al. Among authors: johnson bg. J Pharmacol Exp Ther. 2007 Apr;321(1):308-17. doi: 10.1124/jpet.106.110809. Epub 2007 Jan 4. J Pharmacol Exp Ther. 2007. PMID: 17204749
Metabotropic glutamate receptors in the control of mood disorders.
Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Witkin JM, et al. Among authors: johnson bg. CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. doi: 10.2174/187152707780363302. CNS Neurol Disord Drug Targets. 2007. PMID: 17430147 Review.
137 results